Estudo de eficácia e segurança de ruxolitinibe em pacientes com doença aguda de enxerto vs. hospedeiro refratário a esteróides de grau II a IV
Um estudo multicêntrico de braço único de ruxolitinibe para o tratamento de pacientes chineses com doença aguda do enxerto versus hospedeiro de grau II-IV refratária a corticosteróides
The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroid-refractory acute graft versus host disease (SR-aGvHD).
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Participants will start with a screening period to assess the eligibility; only participants who meet all the inclusion and none of the exclusion criteria will start study treatment from Day 1 to Week 24 or end of treatment. Following safety follow up visits, participants will receive the long-term follow-up until Month 12.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
-
Beijing, China, 100034
- Novartis Investigative Site
-
Beijing, China, 100070
- Novartis Investigative Site
-
Taian, China, 271000
- Novartis Investigative Site
-
Tianjin, China, 300020
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510515
- Novartis Investigative Site
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Novartis Investigative Site
-
-
Shanxi
-
Xian, Shanxi, China, 710061
- Novartis Investigative Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Novartis Investigative Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Key Inclusion criteria
-
Male or female Chinese participants aged 12 or older at the time of informed consent. Written informed consent from participant, parent or legal guardian.
-
Able to swallow tablets.
-
Have undergone alloSCT from any donor source (matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral blood stem cells, or cord blood.
-
Clinically diagnosed Grades II to IV acute GvHD as per standard criteria occurring after alloSCT requiring systemic immune suppressive therapy.
-
Evident myeloid and platelet engraftment (confirmed within 48 hours prior to study treatment (ruxolitinib) start):
-
Confirmed diagnosis of steroid refractory aGvHD defined as participants administered systemic corticosteroids (methylprednisolone at least 1 mg/kg/day [or equivalent prednisone dose at least 1.25 mg/kg/day]), given alone or combined with calcineurin inhibitors (CNI) and either:
-
Progression based on organ assessment after at least 3 days compared to organ stage at the time of initiation of systemic corticosteroid +/- CNI for the treatment of Grade II to IV aGvHD. OR
-
Failure to achieve at a minimum partial response based on organ assessment after 7 days compared to organ stage at the time of initiation of systemic corticosteroid +/-CNI for the treatment of Grade II to IV. OR
-
Participants who fail corticosteroid taper defined as fulfilling either one of the following criteria:
- Requirement for an increase in the corticosteroid dose to methylprednisolone ≥ 1 mg/kg/day (or equivalent prednisone dose ≥ 1.25 mg/kg/day). OR
- Failure to taper the methylprednisolone dose to < 0.5 mg/kg/day (or equivalent prednisone dose <0.6 mg/kg/day) for a minimum of 7 days.
-
Key Exclusion criteria
- Has received more than one systemic treatment for steroid refractory aGvHD. Participants who received JAK inhibitor therapy for any indication after initiation of current alloSCT conditioning.
- Clinical presentation resembling de novo chronic GvHD or GvHD overlap syndrome with both acute and chronic GvHD features.
- Failed prior alloSCT within the past 6 months. Presence of relapsed primary malignancy after the alloSCT was performed.
- Presence of an active uncontrolled infection including significant bacterial, fungal, viral or parasitic infection requiring treatment.
- SR-aGvHD occurring after non-scheduled donor lymphocyte infusion (DLI) administered for pre-emptive treatment of malignancy recurrence. Note: Participants who have received a scheduled DLI as part of their transplant procedure and not for management of malignancy relapse are eligible.
- Presence of significant respiratory disease, severely impaired renal function, clinically significant or uncontrolled cardiac disease, unresolved cholestatic and liver disorders (not attributable to aGvHD). Disorders and/or current therapy with medications that interfere with coagulation or platelet function.
Other protocol-defined inclusion / exclusion criteria may apply
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Ruxolitinib
Participants will receive ruxolitinib orally of 10 mg BID daily (given as two 5-mg tablets, approximately 12 hours apart). |
Ruxolitinib is taken orally daily at 10 mg BID, given as two 5-mg tablets.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall Response Rate (ORR) at Day 28 per Investigators
Prazo: Day 28
|
The ORR at Day 28 defined as the percentage of participants demonstrating a complete response (CR) or partial response (PR) without requirement for additional systemic therapies for an earlier progression, mixed response or nonresponse, according to standard criteria and assessed by investigators. |
Day 28
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Durable Overall response rate (ORR) at Day 56
Prazo: Day 56
|
Durable ORR at Day 56 is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) at Day 28 and maintain a CR or PR at Day 56. |
Day 56
|
|
Duration of Response (DOR)
Prazo: From Week 1 to long term follow up Month 12
|
DOR is defined as the time from first response until aGvHD progression or the date of additional systemic therapies for aGvHD. |
From Week 1 to long term follow up Month 12
|
|
Best overall response (BOR)
Prazo: From week 1 to Day 28
|
Percentage of participants who achieved overall response (complete response (CR) + Partial response (PR) at any time point up to and including Day 28 and before the start of additional systemic therapy for aGvHD. |
From week 1 to Day 28
|
|
Overall survival (OS)
Prazo: From the date of start of study treatment to date of death, up to approx. 12 months
|
Overall survival (OS) is defined as the time from the date of start of study treatment to date of death due to any cause. |
From the date of start of study treatment to date of death, up to approx. 12 months
|
|
Non-relapse mortality (NRM)
Prazo: From date of start of study treatment to date of death, up to approx. 12 months
|
Non-relapse mortality (NRM) is defined as the time from date of start of study treatment to date of death not preceded by hematologic disease relapse/progression. |
From date of start of study treatment to date of death, up to approx. 12 months
|
|
Event-free survival (EFS)
Prazo: From the date of start of study treatment to the date of hematologic disease relapse/progression, graft failure, or death, up to approx. 12 months
|
Event-free survival (EFS) is defined as the time from the date of start of study treatment to the date of hematologic disease relapse/progression, graft failure, or death due to any cause. |
From the date of start of study treatment to the date of hematologic disease relapse/progression, graft failure, or death, up to approx. 12 months
|
|
Failure-free survival (FFS)
Prazo: From the date of start of study treatment to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment, up to approx. 12 months
|
Failure-free survival (FFS) is defined as the time from the date of start of study treatment to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment. |
From the date of start of study treatment to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment, up to approx. 12 months
|
|
Malignancy Relapse/Progression (MR)
Prazo: From date of start of study treatment to hematologic malignancy relapse/progression, up to approx. 12 months
|
Malignancy Relapse/Progression (MR) is defined as the time from date of start of study treatment to hematologic malignancy relapse/progression. Calculated for participants with underlying hematologic malignant disease. |
From date of start of study treatment to hematologic malignancy relapse/progression, up to approx. 12 months
|
|
Reduction of daily corticosteroids dose
Prazo: Up to Day 56
|
This includes the assessment of systemic corticosteroid use and daily dose, and the percentage of participants successfully tapered off all systemic corticosteroids until Day 56, by time intervals and overall. |
Up to Day 56
|
|
Cumulative incidence of chronic GvHD
Prazo: From Week 1 to long term follow up of month 12
|
Cumulative incidence of chronic GvHD (cGvHD) includes mild, moderate and severe occurrences. |
From Week 1 to long term follow up of month 12
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CINC424C2416
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .